Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
Valneva rises after U.K. approval of chikungunya vaccine
Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine.
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada 4 in adults 18 years of age and older.
IXCHIQ Vaccine Approved for Chikungunya Protection
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United
Valneva shares positive phase 3 results for chikungunya vaccine in adolescents
Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older.
UK grants approval for Valneva’s chikungunya vaccine
French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
pharmaphorum3d
CHMP backs Bavarian Nordic's chikungunya jab
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
Nasdaq14d
Valneva Advances IXCHIQ Chikungunya Vaccine To Phase 3 Trial In Children
(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...
Yahoo Finance16d
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
Data from this trial are also expected to support licensure of IXCHIQ ® in Brazil, which would be the first potential approval for use in endemic populations. The one-year VLA1553-321 data showed ...
Hosted on MSN5d
EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers
If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.